Trial Profile
Randomised Double-blind Placebo Controlled Multicenter Clinical Trial of Efficacy and Safety of Ingavirin® Capsules 30mg, in Daily Dose 60mg for the Treatment of Influenza and Other Acute Respiratory Viral Infections at Patients 13-18 y.o.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2017
Price :
$35
*
At a glance
- Drugs Myelo 001 (Primary)
- Indications Influenza virus infections; Respiratory tract infections
- Focus Therapeutic Use
- Sponsors Valenta Pharmaceuticals
- 04 Jul 2017 New trial record